For instance, ctDNA has proven to be particularly valuable in non-small-cell lung cancer, where it helps detect EGFR mutations, enabling clinicians to tailor targeted therapies more effectively and monitor patients’ responses to treatment [109,110]. Here, EGFR is linked to non-small cell lung carcinoma.